Revised 2025 Guidance -- Projected cell processing revenue of $93 million to $94 million, representing 26%-28% growth; total ...

Q3 2025 Earnings Call Transcript November 14, 2025 MiNK Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Q3 2025 Earnings Call Transcript November 13, 2025 zSpace, Inc. misses on earnings expectations. Reported EPS is $-0.26 EPS, expectations were $-0.2. Operator: Hello, and thank you for participating ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Enovis’ third quarter results surpassed Wall Street’s revenue and non-GAAP profit expectations, but the market reacted ...

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look ...

Fate Therapeutics Inc. FATE) on Thursday reported a loss of $32.3 million in its third quarter. The San Diego-based company said it had a loss of 27 cents per share.

Q3 2025 Earnings Call November 13, 2025 5:00 PM ESTCompany ParticipantsPaul Kellenberger - CEO & ChairpersonErick DeOliveira - ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q3 2025 Earnings Call Transcript November 12, 2025 Atea Pharmaceuticals, Inc.

Stem beat on revenue but missed on earnings, causing the stock to sell off in after hours. The company’s net loss of $23.8 million was a marked improvement from $148.3 million in the same quarter last ...

On October 29, 2025, Stem, Inc. released its third quarter earnings, reporting revenue of US$38.24 million, a very large improvement in net loss year-over-year, and updated full-year 2025 revenue ...